For Tuesday, January 10th
COWI, CBAI, GOIG, RIGH, XSNX, BBDA
Our Stocks to Watch tomorrow include CoroWare Inc. (OTCBB: COWI), Cord Blood America Inc. (OTCBB: CBAI), GoIP Global Inc. (OTC: GOIG), Rightsmile Inc. (OTC: RIGH), XsunX Inc. (OTCBB: XSNX) and Bebida Beverage Co. (OTC: BBDA).
COROWARE INCORPORATED (OTCBB: COWI)
"Up 100.00% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/COWI.php
Headquartered in Redmond, Washington, CoroWare is a solutions integrator with expertise in mobile robotics, personal telepresence, IT consulting and software development.
COWI News:
November 22 - CoroWare Reports Third Quarter 2011 Earnings
Gross Revenues Meet Expectations Compared to Year Prior
CoroWare, Inc. (OTCBB: COWI) announced its financial results for the third quarter ending on September 30, 2011.
For the quarter ending on September 30, 2011 ("the 2011 Period"), CoroWare ("the Company") reported revenues of $389,089 compared to revenues of $376,648 during the three-month period ended September 30, 2010 (the "2010 Period"). Revenues were flat compared to the previous year as customers continued to postpone spending on software development services for billing integration, custom engineering, and IT consulting projects in the summer months; purchased CoroCall hosted services instead of videoconferencing infrastructure and room systems; and delayed spending on mobile robotics projects until later in the calendar year.
Gross profit in the 2011 Period was $99,144 (25.5% gross profit percentage) compared to $133,027 (35.3% gross profit percentage) for the 2010 Period. The reduced gross profit percentage resulted from additional personal time off (PTO) during the summer months and unanticipated project warranty expenses.
Research and development spending was $20,372 (5.2% of gross revenues) for the 2011 Period compared to $51,097 (13.6% of gross revenues) in the 2010 Period. The decreased research and development investment resulted from completing our software development and testing initiatives, including CoroCall Communications Cloud Service and CoroWare Billing Integration Framework.
Operating expenses were $274,784 during the 2011 Period compared to $479,376 during the 2010 Period. Sales and marketing expenses were lower in the 2011 Period as the Company adjusted sales compensation plans to bring them in line with the Company's cost of sales objectives. Loss from operations was $175,640 during the 2011 Period compared to a loss of $346,349 in the 2010 Period.
Total other expense was $2,760,329 during the 2011 Period compared to $1,061,716 in the 2010 Period. Other expense is comprised primarily of derivative expenses and amortization of debt discount and deferred finance costs. Net loss for the 2011 Period was $2,935,969 compared to a net loss of $1,408,065 for the 2010 Period.
Net Cash Flows from Operating Activities was negative $57,922 for the 2011 Period compared to negative $2,893 for the 2010 Period. Net Cash Flows from Financing Activities was positive $78,162 for the 2011 Period compared to negative $600 for the 2010 Period.
"Although gross revenues during the summer months were below expectations, we were pleased to see sales begin to rebound in September and October," said Lloyd Spencer , CEO of CoroWare, Inc. "We look forward to continued revenue growth in the fourth quarter as HD videoconferencing infrastructure and room system sales and mobile robot sales improve."
CORD BLOOD AMERICA INCORPORATED (OTCBB: CBAI)
"Up 78.57% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/CBAI.php
Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders.
CBAI News:
January 9 - Advanced Cell Technology and Cord Blood America Poised for Growth in 2012
The Paragon Report Provides Equity Research on Advanced Cell Technology & Cord Blood America
Stem Cell stocks — particularly companies focused on adult stems cells — have performed well of late. Earlier this month Goldman Sachs noted the potential upside of Pluristem Therapeutics — noting that the company does not use the highly controversial embryonic stem cells. The remark from the analyst firm helped drive shares of similar companies that use adult stem cells. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Advanced Cell Technology, Inc. (OTCBB: ACTC) and Cord Blood America, Inc. (OTCBB: CBAI). Access to the full company reports can be found at:
www.paragonreport.com/ACTC
www.paragonreport.com/CBAI
Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. In late December, the company announced that it signed an exclusive agreement to store stem cells at its Las Vegas laboratory for the National Children's Leukemia Foundation (NCLF), New York.
Cord blood stem cells are presently used to treat 75 diseases including leukemia, severe anemia, metabolic blood disorders and immune deficiencies, with ongoing research worldwide to treat many of the world's most serious diseases, including diabetes, heart disease and stroke.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.
Advanced Cell Technology, Inc. applies stem cell-based technologies (both adult and human embryonic) and other proprietary methods in the field of regenerative medicine. In a recent "blog from the chairman" on the company's website, Gary Rabin observes that Advanced Cell Technology now has the distinction of being the only company that is conducting FDA-cleared human clinical trials using human embryonic stem cell-derived therapies. "Both of our ongoing Phase 1/2 trials use human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells, one for Stargardt's macular dystrophy (SMD) and the other for dry age-related macular degeneration (dry AMD)," Rabin explains.
GOIP GLOBAL INCORPORATED (OTC: GOIG)
"Up 100.00% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/GOIG.php
GoIP Global offers a range of services, solutions and tools for brands, agencies, content providers, online portals, entertainment and media companies. GoIP Global offers brand and content customers great flexibility in creating mobile marketing campaigns and applications. Through its subsidiary GO800, LLC, GO800™, a new patent pending text messaging service, which launched in 2010, enables advertisers to incorporate a text prompt in their advertisements, prompting consumers to contact them through a text message rather than calling a 1-800 toll free number.
GOIG News:
October 2 - GoIP's Spin-Off of GOCOM Is Completed
GoIP Global, Inc. (OTC: GOIG) announced that GoIP's Shareholders of record of July 29, 2011 have received spin-off shares of GOCOM. DTC has received 3,884,264 of GOCOM shares for distribution to GoIP shareholders. Any shareholder of record that has not received the share distribution should be contacting their broker.
Ike H. Sutton, GoIP Global's CEO, commented, "Now that the spin-off is complete and shareholders now have ownership in 2 companies, our focus is to finalize an acquisition for GoIP and rebuild GoIP value. There are several opportunities in review which we hope to announce shortly."
RIGHTSMILE INCORPORATED (OTC: RIGH)
"Up 100.00% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/RIGH.php
Based in Port St. Lucie, Florida, RightSmile, Inc. engages in the distribution of branded and private label Cosmetic Laser Teeth Whitening products. RightSmile® provides an exclusive turn-key Cosmetic Teeth Whitening System designed to complement existing health, beauty and medical businesses. Approved branded retailers become known as SmileShoppes. RightSmile® provides every SmileShoppe (RightSmile® dealers) with State-of-the Art Whitening Technology at no cost to the retailer.
RIGH News:
January 9 - RightSmile, Inc. Confirms Reverse Merger Plans with BG Medical Technologies, Inc.
RightSmile, Inc. (OTC: RIGH) confirms reverse merger plans with BG Medical Technologies, Inc., parent company of popular medical cannabis portal, BudGenius.com.
RightSmile entered into merger discussions in October 2011. Since this time BG Medical has worked to complete an ongoing due diligence study of the public entity and market conditions. Throughout December, RightSmile complied with requests and obligations to prepare the public entity for completion of the merger along with formal exit of the RightSmile management team. Full requirements have now been met to the satisfaction of both companies. Final state and corporate filings in Florida and Nevada are progressing for the respective companies. BG Medical Technologies expects to complete the merger January 18th, 2012 . Name change and symbol change requests are to be filed shortly thereafter.
BudGenius.com has served over 240 caregivers for cannabis testing services in California , and provides safety verification and location services for over 2000 patients daily. The company expects to double businesses served and to increase user traffic to over 10,000 visitors daily by mid 2012. Advertising revenue and consumer loyalty programs are being added in Q1, expecting to increase overall revenue 300% by mid-year.
BG Medical Technologies serves its patient community through analysis of responses collected by the BudGenius.com portal in a method similar to traditional scientific trials by harnessing the power of the social Internet. These responses seek to evaluate treatment effectiveness of specific chemical ratios present within the many varieties of cannabis medicine. The resultant data is utilized by BudGenius.com to help guide patients with specific ailments to cannabis medicine varietals that have been evaluated to have a higher probability of favorable treatment.
Services will be expanded throughout 2012 to include diagnostic-support and treatment-monitoring solutions related to cannabis and herbal remedies. These will be introduced as packaged programs to physicians and qualified naturopaths. A program to formulate patient-specific neutraceutical supplements is also underway, and is expected to be introduced by year's end. Supplements will include cannabis and non-cannabis related herbal compounds.
BG Medical Technologies is committed to providing options to patients seeking alternative and supplement treatment to traditional pharmaceutical therapy for critical ailments and general wellness.
None of the statements above made above have been evaluated by the FDA. Furthermore, none of the statements written should be construed as dispensing medical advice or making claims regarding the cure of diseases. Patients should consult a licensed health care professional before starting any supplement or medical program.
XSUNX INCORPORATED (OTCBB: XSNX)
"Up 22.86% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/XSNX.php
Xsunx, Inc., a thin-film photovoltaic (TFPV) company, focuses on developing thin film photovoltaic (TFPV) amorphous silicon solar cell manufacturing processes to produce TFPV solar modules. Its product includes XsunX ASI-120 module, which is a 125 peak watt TFPV solar module utilizing glass substrates and a proprietary semiconductor manufacturing system. XsunX ASI-120 provides for a module delivering high power output, and size and framing that would allow for the use of various existing mounting systems. The target markets for the TFPV solar module include solar farms, government agencies, and utility companies, as well as power purchase agreements and large commercial installations worldwide. The company, formerly known as Sun River Mining, Inc., was incorporated in 1997 and changed its name to XsunX, Inc. in 2003. XsunX is headquartered in Aliso Viejo, California.
XSNX News:
December 29 - XsunX Files Annual Report With SEC
XsunX, Inc. (OTCBB: XSNX) has filed its annual report with the SEC. To view this release, visit http://bit.ly/vaiQgl.
BEBIDA BEVERAGE COMPANY (OTC: BBDA)
"Up 18.18% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/BBDA.php
BeBevCo (Bebida Beverage Company) develops, manufactures and markets beverages including Koma Unwind "Chillaxation Drink™," Koma Unwind Sugar-free "Chillaxation Drink™," and Koma Unwind "Chillaxation Shot™" as well as Potencia Energy Drink, Potencia "BLAST" energy shot and Piranha Water.
BBDA News:
January 5 - BeBevCo Buys Out Redwood Management Convertible Debenture
Bebida Beverage Company (OTC: BBDA) (BeBevCo) a developer, manufacturer and marketer of relaxation and energy drinks announced today that it has reached an agreement with Redwood Management LLC to retire convertible debt that had been purchased by Redwood from Y A Global (Yorkville Advisors). This transaction is the final chapter in eliminating the old convertible note.
This debt had plagued Bebida Beverage Co. since the company changed CEO's in 2009. Over six years old, the debt was re-negotiated by CEO Brian Weber in 2009 from $408,000 to $250,000 and is now reduced to zero. This is the second pre-2009 Convertible Debenture that BebevCo's current CEO and team has eliminated during 2011.
"This is a quantum moment for our Company. We have weathered this storm of dilution to pay off old debts with a lump sum cash payment," said Brian Weber , CEO of BeBevCo.
"Our stock will no longer be at the mercy of the issuance and sales of millions of shares by debt holders. This is a clear message to shareholders that any new share issuances for capitalization benefit the Company and go toward our Brands and growth of the Company only.
"2012 will be a huge year for us and our shareholders. Between all the deals we have completed in North and Central America and now with the expansion to Europe we are on the cusp of a huge growth spurt that will continue into the foreseeable future," Weber went on to say.
|
